Work

Predictors of Mortality in Patients With Multiple Endocrine Neoplasia Type 1

Year: 2025

Type: article

Abstract: OBJECTIVE: Multiple Endocrine Neoplasia Type 1 (MEN 1) is an autosomal dominant disease predisposing to hyperplasia and neoplasia in diverse endocrine tissues. Patients typically present with endocrine abnormalities before the age of 30 years and have reduced life expectancy. Our objective was to determine predictors of premature mortality in MEN 1. DESIGN: Tertiary hospital based retrospective cohort study. PATIENTS: One hundred and thirty patients with a common MEN1 genotype. MEASUREMENTS: Kaplan-Meier survival analysis of median life expectancy (MLE). RESULTS: The overall cohort MLE was 70.8 years. Sex and year of birth were not predictive of survival. A diagnosis before age 45 years of adrenal nodularity (MLE 51.8 years), hypergastrinaemia (MLE 66.2 years), or liver lesions (MLE 38.6) were associated with a significant reduction in survival (26.2 years, p < 0.01, 6.4 years, p = 0.03, and 30.3 years, p < 0.01 respectively) compared to being diagnosed with these conditions later in life. In contrast, diagnosis before age 45 years of pancreatic nodularity (MLE 68.9 years) and primary hyperparathyroidism (MLE 68.9 years) were not predictive of survival. CONCLUSION: Patients with MEN 1 diagnosed before age 45 with adrenal nodularity, hypergastrinaemia or liver lesions had significantly reduced survival. The explanation for non-secretory and benign adrenal macronodular hyperplasia being associated with diminished life expectancy is unclear.

Source: Clinical Endocrinology

DOI: 10.1111/cen.15257

Authors: Jasmine J. Zhu, John R Burgess

Institutions: Royal Hobart Hospital, University of Tasmania

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,250